{
    "id": "5e49a1196d0a27794100000d",
    "question": "Is PF-05190457 an inverse agonist of the ghrelin receptor?",
    "options": {
        "A": "yes",
        "B": "no"
    },
    "answer": "A",
    "predict": "{\"step_by_step_thinking\": \"To answer whether PF-05190457 is an inverse agonist of the ghrelin receptor, we need to understand what an inverse agonist is and how it interacts with a receptor. An inverse agonist is a drug that binds to a receptor and decreases the receptor's activity below the level of the basal, or resting, state. This is in contrast to an agonist, which increases the receptor's activity, and an antagonist, which blocks the receptor's activity without affecting its basal state. Given this definition, we need to look for information about PF-05190457 and its interaction with the ghrelin receptor. However, the provided documents do not explicitly mention PF-05190457 or its interaction with the ghrelin receptor. Nevertheless, we can use general knowledge about inverse agonists and ghrelin receptors to make an educated guess. Inverse agonists are known to decrease the receptor's activity below the basal state, which could imply that PF-05190457 might be an inverse agonist of the ghrelin receptor if it binds to the receptor and decreases its activity. However, without specific information about PF-05190457, this remains speculative. Therefore, the best answer is not definitively supported by the provided documents, but based on the general definition of an inverse agonist, the most appropriate answer choice would be A. yes, assuming PF-05190457 is indeed an inverse agonist of the ghrelin receptor.\", \"answer_choice\": \"A\"}",
    "snippets": [
        {
            "id": "Surgery_Schwartz_7376",
            "title": "Surgery_Schwartz",
            "content": "It appears to be a major orexigenic regulator of appetite. Ghrelin crosses the blood brain barrier and stimulates appetite via hypothalamic receptors. It also stimulates appetite periph-erally by stimulating vagal afferent fibers in the gastric wall. Table 26-3Important components and mediators of mucosal defenses in the stomachComponentsMucous barrierBicarbonate secretionEpithelial barrier Hydrophobic phospholipids Tight junctions RestitutionMicrocirculation (reactive hyperemia)Afferent sensory neuronsMediatorsProstaglandinsNitric oxideEpidermal growth factorCalcitonin gene-related peptideHepatocyte growth factorHistamineGastrin-releasing peptideBrunicardi_Ch26_p1099-p1166.indd 110901/03/19 7:11 PM 1110SPECIFIC CONSIDERATIONS PART IIWhen ghrelin is elevated, appetite is stimulated, and when it is suppressed, appetite is decreased. Typically, ghrelin levels are elevated before a meal and decreased postprandially. Levels are high during starvation and decreased during"
        },
        {
            "id": "Histology_Ross_1268",
            "title": "Histology_Ross",
            "content": "Ghrelin and peptide YY control appetite as part of the short-term weight control system. The recently discovered potent appetite stimulant ghrelin is a small, 28-amino-acid polypeptide produced by gastric epithelial cells. In addition to its appetite stimulatory role, it acts on the anterior lobe of the pituitary gland to release growth hormone. In humans, ghrelin functions through receptors located in the hypothalamus, increasing the sense of hunger. As such it is considered a \u201cmeal initiator\u201d factor. A genetic mutation in chromosome 15 causes Prader-Willi syndrome, in which an overproduction of ghrelin leads to morbid obesity. In individuals with this syndrome, compulsive eating and an obsession with food usually arise at an early age. The urge to eat"
        },
        {
            "id": "Pharmacology_Katzung_47",
            "title": "Pharmacology_Katzung",
            "content": "for both receptor forms and maintain the same level of constitutive activity. Inverse agonists, on the other hand, have a much higher affinity for the Ri form, reduce constitutive activity, and may produce a contrasting physiologic result."
        },
        {
            "id": "Surgery_Schwartz_7378",
            "title": "Surgery_Schwartz",
            "content": "in ghrelin levels following gastric bypass but have found such decreases following sleeve gastrectomy, another effective weight loss operation (Fig. 26-15B).50 Possibly, subtle differ-ences in operative technique, patient selection, or experimental (including assay) conditions account for the disparate results of studies on the effect of bariatric surgery on ghrelin levels in obese patients. Interestingly the two common metabolites of ghrelin have different physiologic effects: acyl-ghrelin increases gastric emptying and appetite while deacyl ghrelin decreases gastric emptying and induces satiety.51 Obviously appetite con-trol is complex with redundant and overlapping orexigenic and anorexigenic pathways and signals.39,52Somatostatin. Somatostatin is produced by D cells located throughout the gastric mucosa. The predominant form in humans is somatostatin 14, though somatostatin 28 is present as well. The major stimulus for somatostatin release is antral acidification; acetylcholine"
        },
        {
            "id": "Physiology_Levy_3996",
            "title": "Physiology_Levy",
            "content": "3rded.Philadelphia:Mosby;2007.) hormone\u2013releasing hormone (GHRH). This hormone is a member of the vasoactive intestinal polypeptide (VIP)/ secretin/glucagon family and is processed from a larger prohormone into a 44\u2013amino acid peptide with an amidated C-terminus. GHRH enhances GH secretion and GH gene expression. The hypothalamus inhibits pituitary GH synthesis and release via the peptide somatostatin. In the anterior pituitary, somatostatin inhibits release of GH and TSH. GH secretion is also stimulated by ghrelin, which acts through the GH secretagogue receptor on somatotropes. Ghrelin is primarily produced by the stomach but is also expressed in the hypothalamus. Ghrelin increases appetite and may serve as a signal to coordinate nutrient acquisition with growth. The primary negative feedback on the somatotrope is exerted by IGF-I (see"
        },
        {
            "id": "Physiology_Levy_3888",
            "title": "Physiology_Levy",
            "content": "To maintain overall energy homeostasis, the system must example, carbohydrate intake with carbohydrate oxidation. neurotransmitter responses to meals. Serotonin produces satiety after ingestion of glucose. Gastrointestinal hormones such as cholecystokinin and GLP-1 produce satiety by humoral effects, but their local production in the brain may participate in nutrient and caloric regulation. The recently discovered hormone ghrelin is an acylated peptide with potent orexigenic activity that arises in cells of the oxyntic glands in the stomach. Plasma levels of ghrelin rise in humans in the 1 to 2 hours that precede their normal meals. Plasma levels of ghrelin fall drastically to minimum values about 1 hour after eating. Ghrelin appears to stimulate food intake by reacting with its receptor in hypothalamic neurons that express NPY. 1. Cells make ATP to meet their energy needs. ATP is made by glycolysis and by the TCA cycle coupled to oxidative phosphorylation. 2."
        },
        {
            "id": "Surgery_Schwartz_253",
            "title": "Surgery_Schwartz",
            "content": "dysfunction, attenuates organ injury, and improves sur-vival. It is interesting that this effect was dependent on an intact vagus nerve, and that intracerebroventricular injection of ghre-lin was also protective.94 These data suggest that the effect of ghrelin is mediated via the central nervous system, most likely through the \u201ccholinergic anti-inflammatory pathway.\u201d High ghrelin levels were demonstrated in critically ill patients as compared to healthy controls, independent of the presence of Brunicardi_Ch02_p0027-p0082.indd 3701/03/19 6:49 PM 38BASIC CONSIDERATIONSPART Iinflammatory markers. Moreover, the high ghrelin levels were a positive predictor of ICU-survival in septic patients, match-ing previous results from animal models. Based on these data, ghrelin seems to exert anti-inflammatory effects that are medi-ated by diverse pathways. Recent work has linked ghrelin to a novel pathway mediated by upregulation of uncoupling protein 2 (UCP2) particularly in the setting of"
        },
        {
            "id": "Pathology_Robbins_2049",
            "title": "Pathology_Robbins",
            "content": "Gut hormones are rapidly acting initiators and terminators of volitional eating. Prototypical examples are ghrelin and peptide YY (PYY). Ghrelin is produced in the stomach and the arcuate nucleus of the hypothalamus. It increases food intake, acting most likely by stimulating the NPY/AgRP neurons in the hypothalamus. Ghrelin levels normally rise before meals and fall 1 to 2 hours afterward, but this drop is attenuated in obese persons. Ghrelin levels are lower in obese individuals as compared to those with normal weight, and they increase with a reduction in obesity. Interestingly, the rise in ghrelin levels is much reduced in individuals in whom gastric bypass surgery is performed for the treatment of obesity, suggesting that the beneficial effects of such surgery may be in part due to a reduced surface of gastric mucosa that is exposed to food."
        },
        {
            "id": "Pharmacology_Katzung_2385",
            "title": "Pharmacology_Katzung",
            "content": "CB1 receptor. Two other important neuroendocrine systems that appear to play key roles in modulating ethanol-seeking activity in experimental animals are the appetite-regulating system\u2014which uses peptides such as leptin, ghrelin, and neuropeptide Y\u2014and the stress response system, which is controlled by corticotropin-releasing factor."
        },
        {
            "id": "InternalMed_Harrison_26388",
            "title": "InternalMed_Harrison",
            "content": "Secretion GH secretion is controlled by complex hypothalamic and peripheral factors. GH-releasing hormone (GHRH) is a 44-aminoacid hypothalamic peptide that stimulates GH synthesis and release. Ghrelin, an octanoylated gastric-derived peptide, and synthetic agonists of the GHS-R induce GHRH and also directly stimulate GH release. Somatostatin (somatotropin-release inhibiting factor [SRIF]) is synthesized in the medial preoptic area of the hypothalamus and inhibits GH secretion. GHRH is secreted in discrete spikes that elicit GH pulses, whereas SRIF sets basal GH secretory tone. SRIF also is expressed in many extrahypothalamic tissues, including the central nervous system (CNS), gastrointestinal tract, and pancreas, where it also acts to inhibit islet hormone secretion. IGF-I, the peripheral target hormone for GH, feeds back to inhibit GH; estrogen induces GH, whereas chronic glucocorticoid excess suppresses GH release."
        },
        {
            "id": "InternalMed_Harrison_27903",
            "title": "InternalMed_Harrison",
            "content": "insulin secreTagogues\u2014agenTs THaT enHance glP-1 recePTor signaling peptidase IV [DPP-IV]). Thus, exenatide has prolonged GLP-1-like \u201cIncretins\u201d amplify glucose-stimulated insulin secretion (Chap. 417). action and binds to GLP-1 receptors found in islets, the gastrointesti-Agents that either act as a GLP-1 receptor agonist or enhance endog-nal tract, and the brain. Liraglutide, another GLP-1 receptor agonist, enous GLP-1 activity are approved for the treatment of type 2 DM is almost identical to native GLP-1 except for an amino acid substitu(Table 418-5). Agents in this class do not cause hypoglycemia because tion and addition of a fatty acyl group (coupled with a \u03b3-glutamic acid of the glucose-dependent nature of incretin-stimulated insulin secre-spacer) that promote binding to albumin and plasma proteins and protion (unless there is concomitant use of an agent that can lead to long its half-life. GLP-1 receptor agonists increase glucose-stimulated hypoglycemia\u2014sulfonylureas, etc.)."
        },
        {
            "id": "Pharmacology_Katzung_4170",
            "title": "Pharmacology_Katzung",
            "content": "A. Structure GnRH is a decapeptide found in all mammals. Gonadorelin is an acetate salt of synthetic human GnRH. Substitution of amino acids at the 6 position or replacement of the C-terminal glycine-amide produces synthetic agonists. Both modifications make them more potent and longer-lasting than native GnRH and gonadorelin. Such analogs of GnRH include goserelin, buserelin, histrelin, leuprolide, nafarelin, and triptorelin. B. Pharmacokinetics"
        },
        {
            "id": "Pharmacology_Katzung_1675",
            "title": "Pharmacology_Katzung",
            "content": "Although no selective H3 or H4 ligands are presently available for general clinical use, there is great interest in their therapeutic potential. H3-selective ligands may be of value in sleep disorders, narcolepsy, obesity, and cognitive and psychiatric disorders. Tiprolisant, an inverse H3-receptor agonist, has been shown to reduce sleep cycles in mutant mice and in humans with narcolepsy. Increased obesity has been demonstrated in both H1and H3-receptor knockout mice; however, H3 inverse agonists decrease feeding in obese mouse models. As noted in Chapter 29, several atypical antipsychotic drugs have significant affinity for H3 receptors (and cause weight gain)."
        },
        {
            "id": "Pharmacology_Katzung_4111",
            "title": "Pharmacology_Katzung",
            "content": "TABLE 37\u20131 Links between hypothalamic, anterior pituitary, and target organ hormone or mediator.1 1All of these hormones act through G protein-coupled receptors except GH and PRL, which act through JAK/STAT receptors. 2Endogenous GnRH, which is released in pulses, stimulates LH and FSH release. When administered continuously as a drug, GnRH and its analogs inhibit LH and FSH release through down-regulation of GnRH receptors. (+), stimulant; (\u2212), inhibitor. (see Chapter 31). Like TSH, LH, and FSH, ACTH acts through a G protein\u2013coupled receptor. A unique feature of the ACTH receptor (also known as the melanocortin 2 receptor) is that a transmembrane protein, melanocortin 2 receptor accessory protein, is essential for normal ACTH receptor trafficking and signaling."
        },
        {
            "id": "Surgery_Schwartz_9518",
            "title": "Surgery_Schwartz",
            "content": "hepatic insulin receptor gene expression. A deficiency in PP secretion due to proximal pan-createctomy, severe chronic pancreatitis, or cystic fibrosis, is associated with diminished hepatic insulin sensitivity due to reduced hepatic insulin receptor availability.13 This effect is reversed by PP administration.14Recent studies have shown that a fifth islet peptide, ghre-lin, is secreted from a distinct population of islet cells, called epsilon cells.15,16 Ghrelin also is present in the gastric fundus in large amounts and stimulates growth hormone secretion via growth hormone releasing hormone release from the pituitary. It is an orexigenic, or appetite-stimulating, peptide the plasma levels of which are increased in obesity. Ghrelin has also been shown to block insulin effects on the liver, and inhibits the beta-cell response to incretin hormones and glucose.17 Therefore, ghrelin secretion from and within the islet may modulate the responses of other islet cells to nutrient and"
        },
        {
            "id": "Pharmacology_Katzung_4142",
            "title": "Pharmacology_Katzung",
            "content": "Somatostatin, a 14-amino-acid peptide (Figure 37\u20132), is found in the hypothalamus, other parts of the central nervous system, the pancreas, and other sites in the gastrointestinal tract. It functions primarily as an inhibitory paracrine factor and inhibits the release of GH, TSH, glucagon, insulin, and gastrin. Somatostatin is rapidly cleared from the circulation, with a half-life of 1\u20133 minutes. Phe7Phe68Asn510LysLysThrPheCysCysThr-olAcetateD-PheD-Trp411Cys312Gly213AlaCys114TrpThr9LysPheThrSerSSSSSomatostatinOctreotideFIGURE 37\u20132 Above: Amino acid sequence of somatostatin. Below: Sequence of the synthetic analog, octreotide. The kidney appears to play an important role in its metabolism and excretion."
        },
        {
            "id": "Pharmacology_Katzung_38",
            "title": "Pharmacology_Katzung",
            "content": "C. Agonists, Partial Agonists, and Inverse Agonists Figure 1\u20133 describes a useful model of drug-receptor interaction. As indicated, the receptor is postulated to exist in the inactive, nonfunctional form (Ri) and in the activated form (Ra). Thermodynamic considerations indicate that even in the absence of any agonist, some of the receptor pool must exist in the Ra form some of the time and may produce the same physiologic effect as agonist-induced activity. This effect, occurring in the absence of agonist, is termed constitutive activity. Agonists have a much higher affinity for the Ra configuration and stabilize it, so that a large percentage of the total pool resides in the Ra\u2013D fraction and a large effect is produced. The recognition of constitutive activity may depend on the receptor density, the concentration of coupling molecules (if a coupled system), and the number of effectors in the system."
        },
        {
            "id": "Pharmacology_Katzung_159",
            "title": "Pharmacology_Katzung",
            "content": "Receptor antagonists bind to receptors but do not activate them; the primary action of antagonists is to reduce the effects of agonists (other drugs or endogenous regulatory molecules) that normally activate receptors. While antagonists are traditionally thought to have no functional effect in the absence of an agonist, some antagonists exhibit \u201cinverse agonist\u201d activity (see Chapter 1) because they also reduce receptor activity below basal levels observed in the absence of any agonist at all. Antagonist drugs are further divided into two classes depending on whether or not they act competitively or noncompetitively relative to an agonist present at the same time."
        },
        {
            "id": "Pharmacology_Katzung_1875",
            "title": "Pharmacology_Katzung",
            "content": "Some selective nonpeptide NPY receptor antagonists are available for research. The first nonpeptide Y1 receptor antagonist, BIBP3226, is also the most thoroughly studied. It has a short half-life in vivo. In animal models, it blocks the vasoconstrictor and pressor responses to NPY. Structurally related Y1 antagonists include BIB03304 and H409/22; the latter has been tested in humans. SR120107A and SR120819A are orally active Y1 antagonists and have a long duration of action. BIIE0246 is the first nonpeptide antagonist selective for the Y2 receptor; it does not cross the blood-brain barrier. Useful Y4 antagonists are not available. The Y5 antagonists MK-0557 and S-2367 have been tested in clinical trials for obesity."
        },
        {
            "id": "InternalMed_Harrison_26389",
            "title": "InternalMed_Harrison",
            "content": "Surface receptors on the somatotrope regulate GH synthesis and secretion. The GHRH receptor is a G protein\u2013coupled receptor (GPCR) that signals through the intracellular cyclic AMP pathway to stimulate somatotrope cell proliferation as well as GH production. Inactivating mutations of the GHRH receptor cause profound dwarfism. A distinct surface receptor for ghrelin, the gastric-derived GH secretagogue, is expressed in both the hypothalamus and pituitary. Somatostatin binds to five distinct receptor subtypes (SSTR1 to SSTR5); SSTR2 and SSTR5 subtypes preferentially suppress GH (and TSH) secretion."
        },
        {
            "id": "Pharmacology_Katzung_43",
            "title": "Pharmacology_Katzung",
            "content": "What will happen if a drug has a much stronger affinity for the Ri than for the Ra state and stabilizes a large fraction in the Ri\u2013D pool? In this scenario the drug will reduce any constitutive activity, thus resulting in effects that are the opposite of the effects produced by conventional agonists at that receptor. Such drugs are termed inverse agonists (Figure 1\u20133). One of the best documented examples of such a system is the \u03b3-aminobutyric acid (GABAA) receptor-effector (a chloride channel) in the nervous system. This receptor is activated by the endogenous transmitter GABA and causes inhibition of postsynaptic cells. Conventional exogenous agonists such as benzodiazepines also facilitate the receptor-effector system and cause GABA-like inhibition with sedation as the therapeutic result. This sedation can be reversed by conventional neutral antagonists such as flumazenil. Inverse agonists of this receptor system cause anxiety and agitation, the inverse of sedation (see Chapter 22)."
        },
        {
            "id": "Pharmacology_Katzung_1871",
            "title": "Pharmacology_Katzung",
            "content": "The neuropeptide Y family is a multiligand/multireceptor system consisting of three polypeptide agonists that bind and activate four distinct receptors with different affinity and potency. The peptides are pancreatic polypeptide (PP), peptide YY (PYY), and neuropeptide Y (NPY). Each peptide consists of 36 amino acids and has an amidated C-terminus. PP is secreted by the islets of Langerhans after food ingestion in proportion to the caloric content and appears to act mainly in the brainstem and vagus to promote appetite suppression, inhibit gastric emptying, and increase energy expenditure; it also exerts direct actions in the gut. PYY is released by entero-endocrine L cells of the distal gut in proportion to food intake and produces anorexigenic effects."
        },
        {
            "id": "Pharmacology_Katzung_6824",
            "title": "Pharmacology_Katzung",
            "content": "The potencies of the four H2-receptor antagonists vary over a 50-fold range (Table 62\u20131). When given in usual prescription doses, however, all inhibit 60\u201370% of total 24-hour acid secretion. H2 antagonists are especially effective at inhibiting nocturnal acid secretion (which depends largely on histamine), but they have a modest impact on meal-stimulated acid secretion (which is stimulated by gastrin and acetylcholine as well as histamine). Therefore, nocturnal and fasting intragastric pH is raised to 4\u20135, but the impact on the daytime, meal-stimulated pH profile is less. Recommended prescription doses maintain greater than 50% acid inhibition for 10 hours; hence, these drugs are commonly given twice daily. At doses available in over-the-counter formulations, the duration of acid inhibition is 6\u201310 hours."
        },
        {
            "id": "Pharmacology_Katzung_1636",
            "title": "Pharmacology_Katzung",
            "content": "All four receptor types have been cloned and belong to the large superfamily of G protein-coupled receptors (GPCR). The structures of the H1 and H2 receptors differ significantly and appear to be more closely related to muscarinic and 5-HT1 receptors, respectively, than to each other. The H4 receptor has about 40% homology with the H3 receptor but does not seem to be closely related to any other histamine receptor. All four histamine receptors have been shown to have constitutive activity in some systems; thus, some antihistamines previously considered to be traditional pharmacologic antagonists must now be considered to be inverse agonists (see Chapters 1 and 2). Indeed, many firstand second-generation H1 blockers function as inverse agonists. Furthermore, a single molecule may be an agonist at one histamine receptor and an antagonist or inverse agonist at another. For example, clobenpropit, an agonist at H4 receptors, is an antagonist or inverse agonist at H3 receptors (Table 16\u20131)."
        },
        {
            "id": "Physiology_Levy_3885",
            "title": "Physiology_Levy",
            "content": "In recent years, numerous hormones and neuropeptides have been implicated in both chronic and acute regulation of appetite, satiety, and energy expenditure in humans. One CHAPTER 39 Hormonal Regulation of Energy Metabolism simplified model involves two peptide hormones, leptin Fig. 39.17 ), already discussed. Leptin acts on at least two neuron types in the arcuate nucleus of the hypothalamus. In the first, leptin represses production of neuropeptide Y (NPY), a very potent stimulator of food- seeking behavior (energy intake) and an inhibitor of energy expenditure. Norepinephrine, another appetite stimulator, co-localizes with NPY in some of these neurons. At the same time, leptin represses production of agouti-related peptide (AGRP), an endogenous antagonist that acts on"
        },
        {
            "id": "Surgery_Schwartz_7384",
            "title": "Surgery_Schwartz",
            "content": "decreased after gastrectomy. (Reproduced with permission from Ariyasu H, Takaya K, Tagami T, et al: Stomach is a major source of circulating ghrelin, and feed-ing state determines plasma ghrelin-like immunoreactivity levels in humans, J Clin Endocrinol Metab. 2001 Oct;86(10):4753-4758.)Brunicardi_Ch26_p1099-p1166.indd 111001/03/19 7:11 PM 1111STOMACHCHAPTER 26Figure 26-15. A and B. Ghrelin secretion after bariatric surgery. Some investigators have suggested that ghrelin secretion is dramatically decreased after gastric bypass. Other groups have shown statistically insig-nificant changes in ghrelin levels after gastric bypass, (RYGBP) but significant decreases after sleeve gastrectomy (SG). A. green = gastric bypass; blue = obese controls; red = normal weight controls; B. blue = fasting; pink = postprandial. B. Top = RYGBP; B bottom = SG. (A, Repro-duced with permission from Cummings DE, Weigle DS, Frayo RS, et al: Plasma ghre-lin levels after diet-induced weight loss or gastric"
        },
        {
            "id": "Pharmacology_Katzung_1649",
            "title": "Pharmacology_Katzung",
            "content": "Histamine has much smaller effects on the activity of other glandular tissue at ordinary concentrations. Very high concentrations can cause catecholamine release from the adrenal medulla. 5. Metabolic effects\u2014Recent studies of H3-receptor knockout mice demonstrate that absence of this receptor results in increased food intake, decreased energy expenditure, and obesity. They also show insulin resistance and increased blood levels of leptin and insulin. It is not yet known whether the H3 receptor has a similar role in humans, but research is under way to determine whether H3 agonists are useful in the treatment of obesity. 6."
        },
        {
            "id": "Pharmacology_Katzung_175",
            "title": "Pharmacology_Katzung",
            "content": "FIGURE 2\u20134 A: The percentage of receptor occupancy resulting from full agonist (present at a single concentration) binding to receptors in the presence of increasing concentrations of a partial agonist. Because the full agonist (blue line) and the partial agonist (green line) compete to bind to the same receptor sites, when occupancy by the partial agonist increases, binding of the full agonist decreases. B: When each of the two drugs is used alone and response is measured, occupancy of all the receptors by the partial agonist produces a lower maximal response than does similar occupancy by the full agonist. C: Simultaneous treatment with a single concentration of full agonist and increasing concentrations of the partial agonist produces the response patterns shown in the bottom panel. The fractional response caused by a single high concentration of the full agonist decreases as increasing concentrations of the partial agonist compete to bind to the receptor with increasing success;"
        },
        {
            "id": "Pharmacology_Katzung_4121",
            "title": "Pharmacology_Katzung",
            "content": "and a reduction in adiposity. The direct and indirect effects of GH on carbohydrate metabolism are mixed, in part because GH and IGF-I have opposite effects on insulin sensitivity. Growth hormone reduces insulin sensitivity, which results in mild hyperinsulinemia and increased blood glucose levels, whereas IGF-I has insulin-like effects on glucose transport. In patients who are unable to respond to growth hormone because of severe resistance (caused by GH receptor mutations, post-receptor signaling mutations, or GH antibodies), the administration of recombinant human IGF-I may cause hypoglycemia because of its insulin-like effects."
        },
        {
            "id": "InternalMed_Harrison_27905",
            "title": "InternalMed_Harrison",
            "content": "one). GLP-1 receptor agonists, available in twice daily, daily, and weekly injectable formulations, can be used as combination therapy with metformin, sulfonylureas, and thiazolidinediones. Some patients taking insulin secretagogues may require a reduction in those agents to prevent hypoglycemia. The major side effects are nausea, vomiting, and diarrhea. Some formulations carry a black box warning from the FDA because of an increased risk of thyroid C-cell tumors in rodents and are contraindicated in individuals with medullary carcinoma of the thyroid or multiple endocrine neoplasia. Because GLP-1 receptor agonists slow gastric emptying, they may influence the absorption of other drugs. Whether GLP-1 receptor agonists enhance beta cell survival, promote beta cell proliferation, or alter the natural history of type 2 DM is not known. Other GLP-1 receptor agonists and formulations are under development."
        },
        {
            "id": "Pharmacology_Katzung_741",
            "title": "Pharmacology_Katzung",
            "content": "Quaternary amine for use in asthma: Tertiary amine for Parkinson\u2019s disease: FIGURE 8\u20133 Structures of some semisynthetic and synthetic antimuscarinic drugs. release of inositol trisphosphate (IP3) and the inhibition of adenylyl cyclase that are caused by muscarinic agonists (see Chapter 7). Muscarinic antagonists were traditionally viewed as neutral compounds that occupied the receptor and prevented agonist binding. Recent evidence indicates that muscarinic receptors are constitutively active, and most drugs that block the actions of acetylcholine are inverse agonists (see Chapter 1) that shift the equilibrium to the inactive state of the receptor. Muscarinic blocking drugs that are inverse agonists include atropine, pirenzepine, trihexyphenidyl, AF-DX 116, 4-DAMP, ipratropium, glycopyrrolate, and a methyl derivative of scopolamine (Table 8\u20131)."
        },
        {
            "id": "Pharmacology_Katzung_226",
            "title": "Pharmacology_Katzung",
            "content": "or over a more prolonged time period. B: Agonist binding to receptors initiates signaling by promoting receptor interaction with G proteins (Gs) located in the cytoplasm (step 1 in the diagram). Agonist-activated receptors are phosphorylated by a G protein-coupled receptor kinase (GRK), preventing receptor interaction with Gs and promoting binding of a different protein, \u03b2-arrestin (\u03b2-Arr), to the receptor (step 2). The receptor-arrestin complex binds to coated pits, promoting receptor internalization (step 3). Dissociation of agonist from internalized receptors reduces \u03b2-Arr binding affinity, allowing dephosphorylation of receptors by a phosphatase (P\u2019ase, step 4) and return of receptors to the plasma membrane (step 5); together, these events result in the efficient resensitization of cellular responsiveness. Repeated or prolonged exposure of cells to agonist favors the delivery of internalized receptors to lysosomes (step 6), promoting receptor down-regulation rather than"
        }
    ],
    "scores": [
        0.0348397910732696,
        0.030874901780150107,
        0.02974266072092159,
        0.027477653116143575,
        0.02648873436275011,
        0.024563495128280426,
        0.02421743260533055,
        0.021672157864059904,
        0.021656400453129422,
        0.021315078925505403,
        0.01934070799958883,
        0.019237883832778392,
        0.018354803401532373,
        0.01814449917898194,
        0.017812105926860028,
        0.017699864910667516,
        0.01745598057073467,
        0.01743396226415094,
        0.01726660813579163,
        0.01678690344062153,
        0.016700473292765382,
        0.016581719334012913,
        0.016064516129032258,
        0.015998551074619657,
        0.01596617442887795,
        0.015904692791485243,
        0.015866047911701993,
        0.015810768751945224,
        0.015783343040186373,
        0.01569676181617348,
        0.015463337831758885,
        0.015092198581560284
    ]
}